1) Imafuku A, Sawa N, Ubara Y, Takaichi K:Acquired hemophilia A that developed during the induction of hemodialysis:the use of double-filtration plasmapheresis. Clin Nephrol 2017;87:147-51
2) Oldenburg J, Mahlangu JN, Kim B, et al:Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377:809-18
3) Shima M, Hanabusa H, Taki M, et al:Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016;374:2044-53
4) Leissinger CA:The literature on inhibitors:Articles that influence my management of patients with hemophilia A and high-titer inhibitors. Am J Hematol 2012;87:S23-6
5) Zeitler H, Ulrich-Merzenich G, Hess L, et al:Treatment of acquired hemophilia by the Bonn-Malmö Protocol:documentation of an in vivo immunomodulating concept. Blood 2005;105:2287-93
6) Freedman J, Garvey MB:Immunoadsorption of factor VIII inhibitors. Curr Opin Hematol 2004;11:327-33
7) Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A:Acquired hemophilia A:review and meta-analysis focused on therapy and prognostic factors. Brit J Haematol 2003;121:21-35
8) Guillet B, Kriaa F, HuysseMG, et al:Protein A sepharose immunoadsorption:immunological and haemostatic effects in two cases of acquired haemophilia. Brit J Haematol 2001;114:837-44
9) Freiburghaus C, Berntorp E, Ekman M, et al:Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999;5:32-9
10) Sunagawa T, Uezu Y, Kadena K, et al:Successful treatment of a non-haemophilic patient with inhibitor to factor VIII by double-filtration plasmapheresis. Brit J Haematol 1999;104:465-7
